O Shaughnessy Asset Management LLC Boosts Position in Biogen Inc. $BIIB

O Shaughnessy Asset Management LLC boosted its holdings in Biogen Inc. (NASDAQ:BIIB) by 83.8% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 110,268 shares of the biotechnology company’s stock after buying an additional 50,279 shares during the period. O Shaughnessy Asset Management LLC owned approximately 0.08% of Biogen worth $19,406,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of BIIB. Caprock Group LLC purchased a new stake in shares of Biogen during the third quarter valued at approximately $742,000. Leuthold Group LLC purchased a new stake in shares of Biogen during the third quarter valued at approximately $3,294,000. Generali Investments Management Co LLC raised its stake in shares of Biogen by 408.2% during the third quarter. Generali Investments Management Co LLC now owns 9,970 shares of the biotechnology company’s stock valued at $1,397,000 after purchasing an additional 8,008 shares during the period. SG Americas Securities LLC raised its stake in shares of Biogen by 1,793.8% during the fourth quarter. SG Americas Securities LLC now owns 183,829 shares of the biotechnology company’s stock valued at $32,352,000 after purchasing an additional 174,122 shares during the period. Finally, TD Asset Management Inc raised its stake in shares of Biogen by 12.7% during the third quarter. TD Asset Management Inc now owns 161,195 shares of the biotechnology company’s stock valued at $22,580,000 after purchasing an additional 18,168 shares during the period. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen Stock Down 1.4%

BIIB stock opened at $192.62 on Tuesday. Biogen Inc. has a twelve month low of $121.05 and a twelve month high of $205.97. The company has a current ratio of 3.06, a quick ratio of 2.41 and a debt-to-equity ratio of 0.34. The company has a market capitalization of $28.44 billion, a P/E ratio of 20.67 and a beta of 0.20. The firm has a 50 day simple moving average of $187.63 and a 200-day simple moving average of $183.63.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, topping analysts’ consensus estimates of $2.95 by $0.62. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The business had revenue of $2.48 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same quarter last year, the company earned $3.02 earnings per share. The business’s quarterly revenue was up 1.9% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, equities research analysts predict that Biogen Inc. will post 14.18 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

BIIB has been the topic of a number of analyst reports. Needham & Company LLC upgraded shares of Biogen from a “hold” rating to a “buy” rating and set a $255.00 price objective on the stock in a research note on Monday. Argus upgraded shares of Biogen to a “hold” rating in a research note on Thursday, April 9th. Weiss Ratings upgraded shares of Biogen from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, May 1st. JPMorgan Chase & Co. raised their price target on shares of Biogen from $175.00 to $185.00 and gave the stock a “neutral” rating in a research report on Thursday, April 23rd. Finally, Mizuho raised their price target on shares of Biogen from $207.00 to $236.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 10th. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Biogen has an average rating of “Moderate Buy” and an average price target of $217.26.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.